slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
V3 region: remarkable variability  “structurally conserved” motifs  vaccine PowerPoint Presentation
Download Presentation
V3 region: remarkable variability  “structurally conserved” motifs  vaccine

Loading in 2 Seconds...

  share
play fullscreen
1 / 3
preston-donovan

V3 region: remarkable variability  “structurally conserved” motifs  vaccine - PowerPoint PPT Presentation

92 Views
Download Presentation
V3 region: remarkable variability  “structurally conserved” motifs  vaccine
An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Amir Maksyutov amaksyutov@yandex.ru Candidate vaccine capable of eliciting broadly reacting antibody response to structurally conserved areas on the HIV-1 V3 region • V3 region: remarkable variability  “structurally conserved” motifs vaccine • Chimeric Peptide Library (CPL) mimic the antigenic variety of V3 region • Immunization with CPL Abs to “structurally conserved” V3 motifs

  2. Amir Maksyutov amaksyutov@yandex.ru RESULTS • CPL was recognized by HIV-1+ • CPL: immunization strong Ab response • Representative peptide panel (RPP): 30 very rare and 5 major variants • strong reactivity with all RPP peptides • broad specificity  covering as very rare as major V3 antigenic variants •  Ab response to the “structurally conserved” V3 motifs

  3. Amir Maksyutov amaksyutov@yandex.ru CONCLUSIONS& PROSPECT • Clinical trial for a mixture of five V3 peptides • Murine HIV-1 challenge system  anti-CPL sera – the most protective we have observed • Broad specificity • Abs to the “structurally conserved” V3 motifs • Design novel vaccine candidates  potentially protective broad Ab response • Therapeutic HIV/AIDS vaccine development